Search
Clinician Ordering Portal
On-demand education
Incorporating DecisionDx-Melanoma into Clinical Practice: Molecular Information for Personalized Management Decisions
Gene Expression Profiling: A Diagnostic Ancillary Test To Aid In The Diagnosis Of Melanocytic Lesions
Dr. Barry White shares cases of challenging melanocytic lesions in which gene expression profiling (GEP) was utilized to inform the diagnosis when histopathological findings were insufficient to render a definitive diagnosis
Utility of GEP in Difficult to Diagnose Melanocytic Lesions
Dr. Drazen Jukic presents challenging cases in which gene expression profiling (GEP) was utilized to inform the diagnosis of ambiguous melanocytic lesions.
DermPath on Demand: Utility of Gene Expression Profiling in Melanocytic Lesions
CME/CE: N/A
Learn About Castle’s Comprehensive Diagnostic Offering
Our suite of highly accurate tests for melanocytic lesions of uncertain potential increases diagnostic confidence and enables better clinical management plans for patients. Learn the essentials from this comprehensive introduction by Matthew Goldberg, MD, Medical Director for Castle Biosciences.
DecisionDx-Melanoma: Predicting Individualized Risk of Recurrence
31-GEP: Sentinel Lymph Node Biopsy Guidance
Castle Biosciences - Revolutionizing Gene Expression Profiling in Clinical Management of Dermatologic Cancers
Use of a Genomic-based Prognostic Tool to Inform Clinical Decisions for Patients with Cutaneous Melanoma
This activity is designed to address the following core and team competencies: Patient Care, Medical Knowledge, Practice-based learning and improvement, Interprofessional Collaboration, and Roles & Responsibilities.
CME/CE: (Credit Expiration Date: July 31st, 2021)